Revenue: As of FY2025 Q3, the actual value is USD 7.543 M, beating the estimate of USD 4.945 M.EPS: As of FY2025 Q3, the actual value is USD -0.28, beating the estimate of USD -0.3122.EBIT: As of FY2025 Q3, the actual value is USD -23.98 M.<h3>Segment Revenue</h3><ul><li>Collaboration and Other Research and Development Revenues: $7.5 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024, primarily due to a milestone achieved under the collaboration with BMS.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $25.1 million for the three months ended September 30, 2025, compared to $62.1 million for the same period in 2024, reflecting a decrease of 60%.</li><li>Operating Loss: $24.5 million for the three months ended September 30, 2025, compared to $65.7 million for the same period in 2024, reflecting a decrease of 51%.</li><li>Research and Development Expenses: $19.8 million for the three months ended September 30, 2025, compared to $47.6 million for the same period in 2024, reflecting a decrease of 58%.</li><li>General and Administrative Expenses: $12.3 million for the three months ended September 30, 2025, compared to $18.1 million for the same period in 2024, reflecting a decrease of 32%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $128.9 million for the nine months ended September 30, 2025, compared to - $159.5 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $138.6 million for the nine months ended September 30, 2025, compared to $131.2 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $23.1 million for the nine months ended September 30, 2025, compared to $0.5 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Restructuring and Impairment Charges: $66.9 million for the nine months ended September 30, 2025, due to the discontinuation of the reni-cel program and workforce reduction.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Editas Medicine, Inc. plans to submit an investigational new drug application for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by the end of 2026.</li><li>Non-Core Business: The company is leveraging partnerships to progress engineered cell medicines to treat various cancers, including collaboration with Bristol Myers Squibb Company.</li></ul>

Editas Medicine | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 7.543 M